Physician profile
Arshad Kaleem
NPI 1134380959
$16,904.89
in general payments reported to CMS, 2019-2025
20 companies · $604 in 2025
The $604 reported for 2025 was more than what 81% of Oral and Maxillofacial Surgery providers received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $78.70 · 2021: $868 · 2022: $1,111 · 2023: $1,648 · 2024: $1,663 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,137 · Travel and Lodging: $721 · Education: $57.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,137.21 |
| Travel and Lodging | $721.23 |
| Education | $57.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axogen | $7,331.62 | 2019-2024 | Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector |
| Kls-Martin L.P. | $5,843.28 | 2019-2025 | |
| Inspire Medical Systems, INC. | $1,206.11 | 2023-2025 | Inspire |
| Depuy Synthes Sales INC. | $722.71 | 2022-2025 | Trumatch, Na |
| Stryker Corporation | $691.16 | 2019-2023 | Na |
| Straumann USA LLC | $248.89 | 2022-2023 | |
| Abbvie INC. | $202.27 | 2021 | |
| Ambu INC. | $118.59 | 2020-2021 | |
| Polynovo North America LLC | $92.33 | 2025 | Novosorb Btm |
| Atos Medical INC | $82.80 | 2024 | Provox Life Home Hme |
| Janssen Biotech, INC. | $65.12 | 2024 | Talvey, Tecvayli, Erleada |
| Kerecis Limited | $64.97 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Medical Device Business Services, INC. | $43.52 | 2021 | |
| Medtronic, INC. | $40.25 | 2024 | Pteye Parathyroid Detection System |
| Astrazeneca Pharmaceuticals LP | $35.46 | 2023-2024 | Tagrisso, Enhertu |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $30.04 | 2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $25.90 | 2024 | |
| Daiichi Sankyo INC. | $23.60 | 2023 | Enhertu |
| Tolmar, INC. | $18.75 | 2023 | |
| Tempus Ai, INC | $17.52 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arshad Kaleem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.